Company intelligence / Profile preview

199 Biotechnologies

London, England, United Kingdom199.bio ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

199 Biotechnologies develops therapies aimed at reversing cellular aspects of aging and treating age-related diseases through epigenetic reprogramming. Their preclinical work demonstrates efficacy in multiple cancer cell lines—especially brain cancers—and they are optimizing both mRNA-based and cell therapy platforms. The company’s organ-on-a-chip system accelerates discovery by simulating human organ systems for high-throughput screening. No clinical results have been published as the company remains at the preclinical research stage.

Therapeutic areas: OtherOncology
Modalities: mRNA therapeuticsCell therapyGene therapy (partial reprogramming)Epigenetic reprogramming
Industry: Biotech

Drug pipeline

1 asset

E-ON-001

Preclinical

Partnerships

Collaborations with University College London (UCL) scientistsstrategic academic partnerships mentioned but not named specifically.

Beyond the preview

Go deeper on 199 Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 199 Biotechnologies.

Explore the full profile